AJM300

EA Pharma Co., Ltd. · Phase 3 active Small molecule Quality 0/100

At a glance

Generic name	AJM300
Also known as	Carotegrast methyl
Sponsor	EA Pharma Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Carotegrast Methyl in Ulcerative Colitis (PHASE4)
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AJM300 CI brief — competitive landscape report
AJM300 updates RSS · CI watch RSS
EA Pharma Co., Ltd. portfolio CI